Daré Bioscience (NASDAQ:DARE – Get Free Report) is expected to announce its earnings results before the market opens on Thursday, March 27th. Analysts expect the company to announce earnings of ($0.66) per share and revenue of $1.00 million for the quarter. Individual that are interested in registering for the company’s earnings conference call can do so using this link.
Daré Bioscience Price Performance
DARE opened at $2.88 on Tuesday. The firm has a market capitalization of $25.06 million, a PE ratio of -4.88 and a beta of 1.38. The business’s 50-day moving average is $3.11 and its two-hundred day moving average is $3.30. Daré Bioscience has a 1 year low of $2.67 and a 1 year high of $7.56.
Wall Street Analysts Forecast Growth
Separately, HC Wainwright reiterated a “buy” rating and set a $12.00 price objective on shares of Daré Bioscience in a research note on Tuesday, December 17th.
Daré Bioscience Company Profile
Daré Bioscience, Inc, a biopharmaceutical company, identifies, develops, and markets products for women's health in the United States. It develops therapies in the areas of contraception, reproductive health, menopause, fertility, and sexual and vaginal health. The company offers XACIATO for the treatment of bacterial vaginosis in female patients 12 years of age and older.
Featured Stories
- Five stocks we like better than Daré Bioscience
- High Flyers: 3 Natural Gas Stocks for March 2022
- Super Micro Stock: $7.2M Call Options Signal Big Upside Potential
- How to start investing in penny stocks
- Top 3 Buy-and-Hold Stocks for 2025: Long-Term Winners to Watch
- What to Know About Investing in Penny Stocks
- D-Wave Stock: Is Quantum Blockchain the Next Big Catalyst?
Receive News & Ratings for Daré Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Daré Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
